Shots:   

• Following recommendations from the EMA’s CHMP & COMP, the EC has approved Akantior to treat AK among adults & adolescents (≥12yrs.)  

• Approval was based on the data from P-III (ODAK) study in AK patients (n=135), published in Ophthalmology, demonstrating that the disease cured in 84.8%, full vision restoration was found in 66.7% with none of them requiring optical cornea transplant and 7.5% needed a therapeutic cornea transplant 

• Avanzanite received the exclusive commercialization rights of Akantior in European Economic Area and Switzerland as per an agreement b/w the company and SIFI 

Ref: SIFI and Avanzanite Bioscience| Image: SIFI and Avanzanite Bioscience 

Related News:- SIFI Reports the CHMP’s Positive Opinion of Akantior (Polihexanide) to Treat Acanthamoeba Keratitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com